Vaxart (VXRT) Competitors $0.38 +0.01 (+1.72%) As of 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VXRT vs. AMRN, FDMT, CADL, DMAC, LRMR, OCGN, TNXP, CAPR, ALT, and FHTXShould you be buying Vaxart stock or one of its competitors? The main competitors of Vaxart include Amarin (AMRN), 4D Molecular Therapeutics (FDMT), Candel Therapeutics (CADL), DiaMedica Therapeutics (DMAC), Larimar Therapeutics (LRMR), Ocugen (OCGN), Tonix Pharmaceuticals (TNXP), Capricor Therapeutics (CAPR), Altimmune (ALT), and Foghorn Therapeutics (FHTX). These companies are all part of the "pharmaceutical products" industry. Vaxart vs. Its Competitors Amarin 4D Molecular Therapeutics Candel Therapeutics DiaMedica Therapeutics Larimar Therapeutics Ocugen Tonix Pharmaceuticals Capricor Therapeutics Altimmune Foghorn Therapeutics Amarin (NASDAQ:AMRN) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations. Which has more risk and volatility, AMRN or VXRT? Amarin has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Vaxart has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Which has preferable valuation and earnings, AMRN or VXRT? Vaxart has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmarin$228.61M1.36-$82.18M-$3.67-4.10Vaxart$47.40M1.86-$66.95M-$0.25-1.54 Is AMRN or VXRT more profitable? Amarin has a net margin of -47.22% compared to Vaxart's net margin of -122.63%. Amarin's return on equity of -21.18% beat Vaxart's return on equity.Company Net Margins Return on Equity Return on Assets Amarin-47.22% -21.18% -15.00% Vaxart -122.63%-91.89%-38.40% Do analysts rate AMRN or VXRT? Amarin currently has a consensus target price of $12.00, indicating a potential downside of 20.21%. Vaxart has a consensus target price of $2.00, indicating a potential upside of 419.48%. Given Vaxart's stronger consensus rating and higher probable upside, analysts clearly believe Vaxart is more favorable than Amarin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Vaxart 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in AMRN or VXRT? 22.3% of Amarin shares are owned by institutional investors. Comparatively, 18.0% of Vaxart shares are owned by institutional investors. 2.0% of Amarin shares are owned by insiders. Comparatively, 2.8% of Vaxart shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media prefer AMRN or VXRT? In the previous week, Amarin and Amarin both had 6 articles in the media. Vaxart's average media sentiment score of 0.13 beat Amarin's score of 0.11 indicating that Vaxart is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Vaxart 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryVaxart beats Amarin on 10 of the 15 factors compared between the two stocks. Get Vaxart News Delivered to You Automatically Sign up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VXRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VXRT vs. The Competition Export to ExcelMetricVaxartMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$88.14M$2.82B$5.75B$9.83BDividend YieldN/A48.51%6.66%4.49%P/E Ratio-1.4322.6482.4426.63Price / Sales1.86720.78530.59110.56Price / CashN/A26.3325.7028.92Price / Book1.486.7910.646.56Net Income-$66.95M$32.94M$3.28B$266.04M7 Day Performance2.94%0.75%-0.08%-0.58%1 Month Performance8.21%8.36%10.35%6.24%1 Year Performance-54.19%0.53%48.99%22.22% Vaxart Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VXRTVaxart2.3701 of 5 stars$0.39+1.7%$2.00+419.5%-56.3%$88.14M$47.40M-1.43120News CoverageGap DownAMRNAmarin0.7087 of 5 stars$15.39-3.7%$12.00-22.0%+21.3%$318.73M$228.61M-4.19360FDMT4D Molecular Therapeutics2.412 of 5 stars$6.74-4.9%$30.40+351.0%-59.1%$314.76M$40K-1.91120News CoverageCADLCandel Therapeutics2.1035 of 5 stars$5.71-4.0%$22.00+285.3%-13.2%$313.48M$120K-8.2860News CoverageAnalyst DowngradeGap DownDMACDiaMedica Therapeutics1.5615 of 5 stars$6.00-1.8%$12.33+105.6%+35.4%$310.13MN/A-8.7020News CoverageAnalyst DowngradeHigh Trading VolumeLRMRLarimar Therapeutics3.1322 of 5 stars$3.72-4.9%$18.43+395.4%-53.1%$307.94MN/A-2.3830Positive NewsOCGNOcugen1.2107 of 5 stars$1.04+3.0%$6.00+476.9%-20.8%$303.99M$4.05M-5.2080News CoverageTNXPTonix Pharmaceuticals3.0267 of 5 stars$34.59-8.9%$70.00+102.4%+20.8%$303.35M$10.09M-0.8850CAPRCapricor Therapeutics2.6931 of 5 stars$6.60-7.0%$22.56+241.8%+38.5%$301.73M$13.39M-4.02101Trending NewsALTAltimmune2.9723 of 5 stars$3.39-4.2%$17.40+413.3%-44.0%$299.20M$20K-2.8750FHTXFoghorn Therapeutics2.9615 of 5 stars$5.25-5.6%$10.67+103.2%-36.2%$296.78M$22.60M-4.41120Positive News Related Companies and Tools Related Companies Amarin Competitors 4D Molecular Therapeutics Competitors Candel Therapeutics Competitors DiaMedica Therapeutics Competitors Larimar Therapeutics Competitors Ocugen Competitors Tonix Pharmaceuticals Competitors Capricor Therapeutics Competitors Altimmune Competitors Foghorn Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VXRT) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxart, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxart With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
